Shares of Viking Therapeutics (NASDAQ: VKTX), a clinical-stage drugmaker working on metabolic treatments, have tripled in value this year. Despite the huge run-up, analysts who follow the company think it has heaps more upside.

The average analyst who follows Viking Therapeutics thinks it can rise to $113.55 per share. Reaching the consensus expectation would result in a gain of about 76% from the stock's recent closing price.

Before opening your brokerage application to take advantage of the mismatch between Wall Street's expectations and the stock's present price, we should learn a thing or two about the experimental drugs in the company's late-stage pipeline.

Continue reading

Source Fool.com